FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 371 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR How can we improve LGBTQ+ cancer care? – That Cancer Conversation... June 27, 2023 如果您剛確診為肺癌患者，請來看看專家的回答 April 22, 2021 EMA Recommends Extension of Therapeutic Indications for Daratumumab October 14, 2024 Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer April 27, 2018 Load more HOT NEWS 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... Changes to chromosomes impact how children’s brain tumours respond to treatment Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors
